Wellington Management Group LLP Has $1.80 Million Stock Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

Wellington Management Group LLP reduced its stake in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) by 14.8% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 136,714 shares of the company’s stock after selling 23,730 shares during the quarter. Wellington Management Group LLP owned 0.31% of Y-mAbs Therapeutics worth $1,798,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. State Street Corp increased its stake in Y-mAbs Therapeutics by 50.4% in the third quarter. State Street Corp now owns 1,209,781 shares of the company’s stock valued at $15,909,000 after acquiring an additional 405,169 shares during the last quarter. Caligan Partners LP increased its stake in shares of Y-mAbs Therapeutics by 105.3% in the 3rd quarter. Caligan Partners LP now owns 1,195,253 shares of the company’s stock valued at $15,718,000 after purchasing an additional 613,175 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Y-mAbs Therapeutics during the 3rd quarter worth $44,000. FMR LLC lifted its position in shares of Y-mAbs Therapeutics by 23.1% during the 3rd quarter. FMR LLC now owns 36,416 shares of the company’s stock worth $479,000 after buying an additional 6,822 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in Y-mAbs Therapeutics by 9.4% in the third quarter. Charles Schwab Investment Management Inc. now owns 279,577 shares of the company’s stock valued at $3,676,000 after buying an additional 23,982 shares in the last quarter. Institutional investors own 70.85% of the company’s stock.

Y-mAbs Therapeutics Trading Down 7.9 %

Shares of YMAB opened at $8.78 on Thursday. The stock’s 50-day moving average price is $12.69 and its two-hundred day moving average price is $12.65. Y-mAbs Therapeutics, Inc. has a 12 month low of $6.09 and a 12 month high of $20.90. The company has a market capitalization of $393.25 million, a PE ratio of -16.26 and a beta of 0.61.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its quarterly earnings data on Friday, November 8th. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). The company had revenue of $18.46 million during the quarter, compared to analyst estimates of $23.38 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same period in the prior year, the firm earned ($0.18) earnings per share. Equities research analysts predict that Y-mAbs Therapeutics, Inc. will post -0.66 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. HC Wainwright reissued a “buy” rating on shares of Y-mAbs Therapeutics in a report on Wednesday, December 11th. Cantor Fitzgerald reissued an “overweight” rating and issued a $20.00 price objective on shares of Y-mAbs Therapeutics in a research note on Monday, September 9th. Oppenheimer assumed coverage on shares of Y-mAbs Therapeutics in a research note on Monday, November 18th. They set an “outperform” rating and a $23.00 target price on the stock. Wedbush reiterated an “outperform” rating and issued a $23.00 price target on shares of Y-mAbs Therapeutics in a research note on Tuesday, September 10th. Finally, Brookline Capital Management began coverage on Y-mAbs Therapeutics in a research report on Thursday, December 5th. They set a “buy” rating and a $17.00 price objective on the stock. One research analyst has rated the stock with a sell rating, seven have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $20.89.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.